On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

In Featured on App, Regulation and Policy by CecileLeave a Comment

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

The FDA has lifted a temporary ‘halt in research’ placed on the Ebola drug that has been¬†developed by Canadian company Tekmira Pharmaceuticals. The lift of this hold means that the experimental drug may potentially be used on people infected with Ebola amidst the current outbreak in West Africa.

The hold, although partially lifted, still remains in part. Tekmira still cannot carry out its intentions for a multi-ascending dose portion of a phase 1 trial in health volunteers.

The rapid development of Ebola treatment candidates across the US and Europe looks to lending itself to a cure in the near future.

Read more about it here:¬†FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold

Leave a Comment

Current ye@r *